Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
30.37
Price to sales ratio
5.08

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
505
TAK
Takeda Pharmaceutical Company Limited American Depositary Share
16.46 USD-0.60%-2.83%+2.88%+16.04%25.64 B USD
613
VTRS
Viatris Inc. - Common Stock
16.39 USD+0.74%-2.96%-0.49%+58.36%19.09 B USD
794
ELAN
Elanco Animal Health Incorporated Common Stock
24.96 USD+0.56%-0.64%+2.38%+11.45%12.47 B USD
874
RDY
Dr. Reddy's Laboratories Ltd
12.99 USD-1.59%-9.48%-2.77%-10.78%10.84 B USD

Frequently asked questions about Neurocrine Biosciences, Inc. - Common Stock

What is the Neurocrine Biosciences, Inc. - Common Stock stock price today?

The current price of Neurocrine Biosciences, Inc. - Common Stock (NBIX) is 173.65. Over the past 24 hours, the stock has changed by -1.95%. Follow the NBIX chart for real-time price dynamics.

What is the stock ticker of Neurocrine Biosciences, Inc. - Common Stock?

Neurocrine Biosciences, Inc. - Common Stock trades under the ticker NBIX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Neurocrine Biosciences, Inc. - Common Stock stock going up?

NBIX has changed by -0.60% over the last week, +7.16% over the last month, and +19.76% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Neurocrine Biosciences, Inc. - Common Stock net income for the last quarter?

Neurocrine Biosciences, Inc. - Common Stock reported net income of 197.9 M for the last quarter. The previous quarter showed 153.7 M, which means net income changed by +28.76%.

How many employees does Neurocrine Biosciences, Inc. - Common Stock have?

As of the latest available data, Neurocrine Biosciences, Inc. - Common Stock has 2 000 employees. Workforce size can provide additional context about the company's scale and operations.

What is Neurocrine Biosciences, Inc. - Common Stock EBITDA?

Neurocrine Biosciences, Inc. - Common Stock EBITDA is 199.4 M, and its EBITDA margin is 24.48%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Neurocrine Biosciences, Inc. - Common Stock stock?

You can buy Neurocrine Biosciences, Inc. - Common Stock (NBIX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Neurocrine Biosciences, Inc. - Common Stock stock?

Investing in Neurocrine Biosciences, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the NBIX chart and related analysis on metatrader.com as part of your research.

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

News